Astera Labs, Inc. (ALAB)
NASDAQ:ALAB
Top Page
Astera Labs, Inc.
(NASDAQ:ALAB)
Select Model
Select Model
Rating:77Outperform
Price Target:
$124.00
▲(16.62% Upside)
Action:ReiteratedDate:02/12/26
The score is driven primarily by strong 2025 financial performance (profitability and free cash flow) and a constructive earnings outlook with continued growth visibility. These positives are tempered by a premium valuation and mixed-to-cooling technical momentum despite an overall uptrend.
Positive Factors
Balance sheet strength
Astera’s near-zero leverage, large equity base and ample cash provide durable financial flexibility to fund multi-year R&D, support customer programs and absorb milestone timing slippage. A clean capital structure lowers refinancing risk and materially increases runway for strategic investments.
Negative Factors
Sustained operating expense step-up
Management is accelerating hiring and R&D investment, which increases the company’s fixed cost base and requires continued revenue growth to preserve margins. If product ramps or customer milestones slip, the elevated OpEx cadence can pressure operating profitability and cash generation durability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Astera’s near-zero leverage, large equity base and ample cash provide durable financial flexibility to fund multi-year R&D, support customer programs and absorb milestone timing slippage. A clean capital structure lowers refinancing risk and materially increases runway for strategic investments.
Read all positive factors
Astera Labs, Inc. (ALAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.10B
Dividend YieldN/A
Average Volume (3M)4.44M
Price to Earnings (P/E)126.3
Beta (1Y)2.48
Revenue Growth136.51%
EPS GrowthN/A
CountryUS
Employees440
SectorTechnology
Sector Strength88
IndustrySemiconductors
Share Statistics
EPS (TTM)0.58
Shares Outstanding170,214,510
10 Day Avg. Volume4,233,921
30 Day Avg. Volume4,439,451
Financial Highlights & Ratios
PEG Ratio-0.41
Price to Book (P/B)20.30
Price to Sales (P/S)32.47
P/FCF Ratio98.25
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue21.07
Enterprise Value/Gross Profit27.84
Enterprise Value/Ebitda88.20
Forecast
1Y Price Target
$207.50Price Target Upside95.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)2.47
Revenue Forecast (FY)$1.35B
Astera Labs, Inc. Business Overview & Revenue Model
Company Description
Astera Labs, Inc. designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, wh...
How the Company Makes Money
Astera Labs primarily makes money by selling semiconductor products used for high-speed connectivity in servers and AI/data-center platforms. Revenue is generated from product sales to system and component manufacturers (and/or via distribution ch...
Astera Labs, Inc. Earnings Call Summary
Earnings Call Date:Feb 10, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call presented strong operational and financial momentum: large revenue and unit growth across multiple product families (Scorpio, Ares, Taurus), robust margins, a healthy cash position, major hyperscaler engagements (including a warrant tied to up to $6.5B) and strategic partnerships (CXL on Azure). Management is accelerating R&D and hiring to capture an expanded TAM and new markets (optical, custom connectivity), accepting near-term OpEx increases to support long-term revenue opportunities. Primary negatives are a material step-up in operating expenses, modest near-term margin pressure from hardware mix and warrant accounting, and multi-year timing/technology adoption risks (UA Link vs ESON, optical adoption around 2028). Overall, highlights substantially outweigh lowlights given the magnitude of revenue growth, cash balance, and product traction.Positive Updates
Strong Revenue Growth (Q4 and FY2025)
Q4 revenue of $270.6M, up 17% sequentially and up 92% year-over-year; full-year 2025 revenue of $852.5M, up 115% versus prior year.
Negative Updates
Rising Operating Expenses
Q4 non-GAAP operating expenses were $96M, up $16M sequentially, driven by R&D expansion (R&D $70.7M). Q1 2026 non-GAAP OpEx guidance rises materially to $112M–$118M, reflecting an accelerated investment cadence.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth (Q4 and FY2025)
Q4 revenue of $270.6M, up 17% sequentially and up 92% year-over-year; full-year 2025 revenue of $852.5M, up 115% versus prior year.
Read all positive updates
Company Guidance
Astera Labs guided Q1 2026 revenue of $286–$297 million (up ~6–10% sequentially from Q4’s $270.6M and against FY25 revenue of $852.5M), non‑GAAP gross margin of ~74% (Q4: 75.7%, down 70 bps), non‑GAAP operating expenses of ~$112–$118M (Q4: $96M; Q4 R&D $70.7M, S&M $11.1M, G&A $14.2M), interest income of ~ $11M (Q4: $12M), a non‑GAAP tax rate of ~12% (Q4: 13%), a non‑GAAP fully diluted share count of ~184M (Q4: 181.2M), and non‑GAAP diluted EPS of ~$0.53–$0.54 (Q4: $0.58); management said Ares, Taurus and Scorpio will drive Q1 growth, the OpEx step‑up funds R&D hires and an Israel design center (including an AQUI hire), the company ended Q4 with $1.19B cash and $95.3M cash flow from operations, and it is modeling roughly a ~2‑point per‑quarter non‑cash gross‑margin impact beginning in Q2 related to warrants (3.3M shares tied to up to $6.5B of customer purchases).Astera Labs, Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 852.52M | 396.29M | 115.79M | 79.87M |
| Gross Profit | 645.26M | 302.70M | 79.83M | 58.68M |
| EBITDA | 224.98M | -112.91M | -27.72M | -59.39M |
| Net Income | 219.13M | -83.42M | -26.26M | -58.34M |
Balance Sheet | ||||
| Total Assets | 1.53B | 1.05B | 196.29M | 211.73M |
| Cash, Cash Equivalents and Short-Term Investments | 1.19B | 914.30M | 149.31M | 163.14M |
| Total Debt | 35.15M | 1.29M | 2.93M | 1.60M |
| Total Liabilities | 168.19M | 89.71M | 38.87M | 297.02M |
| Stockholders Equity | 1.36B | 964.80M | 157.43M | -85.29M |
Cash Flow | ||||
| Free Cash Flow | 281.76M | 102.43M | -15.48M | -39.77M |
| Operating Cash Flow | 319.31M | 136.68M | -12.72M | -35.90M |
| Investing Cash Flow | -241.47M | -757.57M | -17.77M | -90.59M |
| Financing Cash Flow | 9.80M | 655.84M | -502.00K | 151.67M |
Astera Labs, Inc. Technical Analysis
Negative
106.33
Price Trends
134.73
Negative
147.48
Negative
154.74
Negative
Market Momentum
-6.72
Positive
39.07
Neutral
25.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALAB, the sentiment is Negative. The current price of 106.33 is below the 20-day moving average (MA) of 118.74, below the 50-day MA of 134.73, and below the 200-day MA of 154.74, indicating a bearish trend. The MACD of -6.72 indicates Positive momentum. The RSI at 39.07 is Neutral, neither overbought nor oversold. The STOCH value of 25.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALAB.
Astera Labs, Inc. Risk Analysis
Astera Labs, Inc. disclosed 64 risk factors in its most recent earnings report. Astera Labs, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
We have rapidly grown as a business in dynamic and rapidly evolving markets, and we may have difficulty accurately predicting our future revenue for the purpose of appropriately budgeting and adjusting our expenses. Q4, 2025
Astera Labs, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $18.10B | 126.33 | 18.21% | ― | 136.51% | ― | |
75 Outperform | $93.30B | 25.45 | 19.38% | 0.28% | 44.95% | ― | |
64 Neutral | $24.51B | 183.93 | 1.53% | ― | -16.13% | -81.06% | |
63 Neutral | $49.42B | 27.14 | 20.73% | 1.79% | -6.81% | -23.16% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
58 Neutral | $35.38B | 246.12 | -1.42% | 2.79% | -23.36% | -131.15% | |
56 Neutral | $30.86B | -216.33 | 0.97% | 1.28% | -17.33% | -76.71% |
* Technology Sector Average
ALAB
Astera Labs, Inc.
106.33
42.25
65.93%
MRVL
Marvell
106.71
43.69
69.33%
MCHP
Microchip
65.38
17.87
37.62%
NXPI
NXP Semiconductors
195.58
5.53
2.91%
ON
ON Semiconductor
62.20
21.44
52.60%
STM
STMicroelectronics
34.52
12.84
59.24%
Astera Labs, Inc. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Astera Labs Grants Amazon Strategic Performance-Based Warrant Investment
Positive
Feb 10, 2026
On February 5, 2026, Astera Labs, Inc. entered into a Transaction Agreement with Amazon.com, Inc. and a related Warrant Agreement with Amazon.com NV Investment Holdings LLC, allowing Amazon’s investment arm to acquire up to 3,262,299 Astera ...
Executive/Board Changes
Astera Labs Appoints Germaine Cota as Chief Accounting Officer
Positive
Jan 20, 2026
On January 20, 2026, Astera Labs, Inc. appointed Germaine Cota as Chief Accounting Officer and Vice President of Finance, making her the company’s principal accounting officer for SEC reporting purposes. Cota brings extensive finance and acc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.